MARKET

ARQT

ARQT

Arcutis Biotherapeutics, Inc.
NASDAQ
20.86
-0.15
-0.71%
After Hours: 20.56 -0.3 -1.42% 19:52 05/22 EDT
OPEN
21.01
PREV CLOSE
21.01
HIGH
21.41
LOW
20.63
VOLUME
1.16M
TURNOVER
--
52 WEEK HIGH
31.77
52 WEEK LOW
12.72
MARKET CAP
2.61B
P/E (TTM)
-993.3333
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ARQT last week (0511-0515)?
Weekly Report · 6d ago
Is Strong Q1 Growth and Reaffirmed Guidance Altering The Investment Case For Arcutis Biotherapeutics (ARQT)?
Simply Wall St · 6d ago
Arcutis Biotherapeutics: The Dermatology Platform Is Starting To Compound
Seeking Alpha · 05/15 11:54
Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT), Centessa Pharmaceuticals (CNTA) and Radnet (RDNT)
TipRanks · 05/11 12:40
Weekly Report: what happened at ARQT last week (0504-0508)?
Weekly Report · 05/11 10:16
A Look At Arcutis Biotherapeutics (ARQT) Valuation After Q1 2026 Results And ZORYVE Label Expansion Efforts
Simply Wall St · 05/11 03:20
Arcutis Earnings Call Signals Momentum Amid Headwinds
TipRanks · 05/11 00:23
Arcutis Biotherapeutics (ARQT) Is Down 11.0% After Reaffirming 2026 Guidance And Advancing ZORYVE sNDA
Simply Wall St · 05/09 11:48
More
About ARQT
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company develops therapies against biologically validated targets and produces a pipeline for a range of inflammatory dermatological conditions. Its portfolio consists of topical and systemic treatments to treat immune-mediated dermatological diseases and conditions. Its product portfolio includes ZORYVE Roflumilast Cream, ZORYVE Roflumilast Foam, and ARQ-234. The ZORYVE Roflumilast Cream is used for the treatment of seborrheic dermatitis in individuals aged 9 years and older. The ZORYVE Roflumilast Foam for the topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients 6 years of age and older. The ARQ-234 is a fusion protein that is a checkpoint agonist of the CD200 Receptor (CD200R). CD200R is an immune-regulatory receptor which is an immunological checkpoint with a role in the maintenance of immune tolerance.

Webull offers Arcutis Biotherapeutics Inc stock information, including NASDAQ: ARQT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARQT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARQT stock methods without spending real money on the virtual paper trading platform.